All In Biotech

NDA 206406 · Veloxis Pharms INC

Envarsus Xr

Tacrolimus · Oral

Orphan

Last checked: Nov 19, 2026Latest source record: Apr 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jul 10, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,405

234 Phase 3, 122 recruiting

FAERS reports

131,679

118,245 serious, 20,659 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death [see Warnings and Precautions (5.1 , 5.2 )]. WARNING: MALIGNANCIES AND SERIOUS INFECTIONS See full prescribing information for complete boxed warning. Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 )

What it is approved for

From the label in effect Feb 26, 2025.

ENVARSUS XR is a calcineurin-inhibitor immunosuppressant indicated for: The prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants ( 1.1 ) The prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants ( 1.2 ) 1.1 Prophylaxis of Organ Rejection in De Novo Kidney Transplant Patients ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants [see Clinical Studies (14.1) ]. 1.2 Prophylaxis of Organ Rejection in Stable Kidney Transplant Patients Converting from Immediate-Release Formulations ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants [see Clinical Studies (14.2) ].

Mechanism: Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (an ubiquitous mammalian intracellular enzyme) is then formed and the phosphatase activity of calcineurin inhibited. Such inhibition prevents the dephosphorylation and translocation of various factors such as the nuclear factor of activated T-cells (NF-AT) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). Tacrolimus inhibits the expression and/or production of several cytokines that include interleukin (IL)-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ENVARSUS XR · TACROLIMUS EQ 1MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • ENVARSUS XR · TACROLIMUS EQ 4MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • ENVARSUS XR · TACROLIMUS EQ 0.75MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tacrolimus" as an intervention, any sponsor and status, largest first.

All 1,405 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use13,632
  • drug ineffective9,158
  • product use in unapproved indication6,247
  • drug interaction5,771
  • acute kidney injury5,731
  • diarrhoea4,761
  • transplant rejection4,365
  • cytomegalovirus infection4,225
  • pyrexia3,958
  • covid-193,872
  • toxicity to various agents3,789
  • pneumonia3,755

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004169
2005219
2006259
2007555
2008951
20091,053
20101,201
20112,205
20122,459
20131,608
20142,523
20153,011
20164,273
20176,324
20189,468
20199,832
202011,792
202111,245
202211,517
202312,900
202414,007
202513,919
202610,189

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Envarsus XR (Tacrolimus)

2024 spending

$16.9M

Beneficiaries

3,091

19,015 claims

Per beneficiary

$5,459

$11.03 per unit

View as table
YearSpending
2020$6,260,513
2021$7,870,982
2022$10,310,900
2023$13,046,575
2024$16,874,072

Part B: Envarsus Xr (Tacrolimus) · HCPCS J7503

2024 spending

$120M

Beneficiaries

15,740

170,798 claims

Per beneficiary

$7,627

2024 ASP limit $1.75 per unit

View as table
YearSpending
2020$84,669,517
2021$102,552,113
2022$107,358,459
2023$114,823,107
2024$120,049,348

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,850 on PubMed

Sponsor: Veloxis Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.